Detalhe da pesquisa
1.
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Clin Cancer Res
; 29(18): 3706-3716, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327320